NCT07130903View on ClinicalTrials.gov

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

April 17, 2028

Study Completion Date

April 17, 2030

Conditions
Metastatic Colorectal Adenocarcinoma
Interventions
DRUG

Fruquintinib

Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class

DEVICE

TheraBionic P1

TheraBionic P1 is a amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) device

Trial Locations (1)

48201

RECRUITING

Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

THERABIONIC INC.

OTHER

lead

Barbara Ann Karmanos Cancer Institute

OTHER